Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120

This Phase 2b study enrolled 51 patients at 11 medical centers throughout the United States.

San Diego-based biotechnology company Ceregene, Inc. has completed enrollment in its Phase 2b trial of CERE-120, a gene therapy product expressing the neurturin (NRTN) gene for the treatment of Parkinson's disease.

This Phase 2b study enrolled 51 patients at 11 medical centers throughout the United States. CERE-120 is comprised of an AAV vector intended to provide constant, sustained expression of neurturin (NRTN), a neurotrophic factor shown to rescue dying dopaminergic neurons, restoring their function and protecting them from cell death.

"Safely completing enrollment in our current Phase 2b CERE-120 Parkinson's study is an important milestone in Ceregene's history, as this study builds on the results of an earlier Phase 2 trial and is powered t